“Thrilled to share a powerful new scientific review authored by Dr. Biswanath Majumder, PhD, titled “Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation.”
Dr. Majumder leads Aryastha’s Immunotherapy–Oncology Division, and his work continues to advance our scientific direction. Just a few weeks ago, our team showcased our BioSolution® platform at the SITC Annual Meeting in Maryland, USA, underscoring Aryastha’s commitment to next-generation immunotherapy innovation.
This timely article explores how the adenosine signaling axis—driven by enzymes like CD39/CD73 and receptors A2AR/A2BR—acts as a critical immunosuppressive checkpoint within the tumor immune microenvironment (TIME). The review provides deep scientific clarity on how adenosine accumulation contributes to T-cell exhaustion, myeloid cell dysfunction, and resistance to established immunotherapies. Importantly, it highlights the emerging therapeutic landscape targeting the adenosine pathway, including receptor antagonists, enzyme inhibitors, and combination strategies with checkpoint inhibitors, CAR-T therapies, vaccines, and metabolic modulators. As the field pushes beyond traditional checkpoints, this pathway stands out as a promising frontier for reshaping cancer treatment.
A must-read for anyone following the future of cancer immunology and translational research.
